UBS Group’s Nuvation Bio NUVB Stock Holding History

UBS Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.2M	Buy	+6,374,705	New	+$31.2M	﹤0.01%	2074

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS Group's NUVB Position: Q2 2026 in Review

UBS Group reduced its Nuvation Bio (NUVB) stake by 19% in Q2 2026, selling an estimated $1.26M and leaving 1,116,881 shares worth $6.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

UBS Group first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

UBS Group held 1,116,881 shares of Nuvation Bio worth $6.34M as of Q2 2026.
UBS Group sold 257,066 Nuvation Bio shares in Q2 2026, an estimated $1.26M.
Nuvation Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3912 holding.
UBS Group first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.